Recent Updates
Recently added Catalysts

GEO-CM04S1

Phase 2

COVID-19 Infection | Monoclonal antibody | Oncology |GeoVax Labs, Inc.|Last Updated: Feb 10, 2026

Target and mechanism

ModalityMonoclonal antibody

Also known as Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment63

FDA Designations

No designations recorded

Clinical trial landscape

GEO-CM04S1 · 1 trial · 5 indications

Phase 2 1
NCT04977024SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood CancerCOVID-19 Infection
ACTIVE NOT_RECRUITING63 Analytics
PHASE2ACTIVE NOT_RECRUITING
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
COVID-19 Infection
NCT0497702463
Unlock trial analytics

Study Design & Arms

Interventions

NameTypeDescription
COVID-19 VaccineBIOLOGICALReceive SOC mRNA SARS-CoV-2 vaccine IM
Diagnostic Laboratory Biomarker AnalysisOTHERCorrelative studies
Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1BIOLOGICALGiven IM
Unlock Study Design Details